Tyrosine Kinases as Druggable Targets in Cancer / / edited by Huan Ren.
Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | London, United Kingdom : : IntechOpen,, 2019. |
| Year of Publication: | 2019 |
| Language: | English |
| Physical Description: | 1 online resource (134 pages) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment. |
|---|---|
| ISBN: | 1839622199 1789848091 |
| Hierarchical level: | Monograph |
| Statement of Responsibility: | edited by Huan Ren. |